FDA Tries to Clear Up Continuous Manufacturing Ambiguities
This article was originally published in The Gold Sheet
Executive Summary
FDA seeks “creative” solutions to clear up the regulatory ambiguities associated with continuous manufacturing. Agency also notes “teething problems” with continuous manufacturing implementation.
You may also be interested in...
US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing
Agency documents its regulatory science accomplishments to advance product development and manufacturing and ensure the safety and effectiveness of marketed products.
Focus On Equipment And Software For Validating Continuous Manufacturing Processes – FDA
US FDA officials outline the agency’s expectations for validating processes for drugs manufactured on a continuous line and see growing interest among manufacturers in developing continuous manufacturing systems.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”